login
Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

An inside view into the FAST trial


Wednesday, 08 Feb 2012 12:00
Manuel Castella
Manuel Castella


By Manuel Castella


Since time that the FAST trial1 was designed in 2007, up to now, there has not been clear evidence to indicate ablation treatments aside from the control of symptoms.2,3 Nevertheless, catheter ablation has expanded its indications thanks to increasing evidence that it is significantly more effective at maintaining sinus rhythm than drug therapy. The expanded indication of catheter ablation has been reflected in the 2011 ACC/AHA/ESC guidelines.3


Although catheter ablation has become a routine treatment for symptomatic atrial fibrillation, two questions arise. First, what is the efficacy to indicate this therapy in patients with left atrium dilatation or with a previous failed catheter ablation? In the FAST trial, two centres with great experience in catheter ablation showed poor results in this subgroup of patients, with 36% actual freedom of arrhythmia at one year.


Thoracoscopic surgery applies the same principles that are applied to catheter ablation to treat atrial fibrillation. Its main difference is that radiofrequency is applied through a bipolar clamp that produces a linear, transmural lesion at the antrum of the pulmonary veins. This avoids most of the dangerous complications in catheter ablation, such as oesophagus lesions or pulmonary vein stenosis. Other lines can be preformed to resemble the Cox-Maze lesion set, but these are made with monopolar radiofrequency; therefore, the possibility of gaps in the line or lack of transmurality exists as in catheter ablation.


Complications in patients in the surgical branch were high in the FAST trial. Interestingly, most of them were due to the essence of it being a new surgical procedure rather than to the technology applied, and therefore a certain learning curve must be appointed.


The agreement by the principal investigators were to start randomising patients after 10 surgeries and, indeed, our first randomised patient in Barcelona was our 11th case. But learning curves are not only about technique. Our anticoagulation protocol started on the third day after surgery. When a patient developed a haemianopsia due to an occipital ischaemic stroke at postoperative day three, we decided to anticoagulate six hours after surgery, and soon after a patient developed an important haemothorax. Our protocol changed to oral anticoagulation at postop day two and after that, we had no more haemorrhagic or ischaemic episodes in more than 50 patients. We are still in a learning process, like catheter ablation was several years ago, when in 2005 the worldwide survey presented a major complications rate of 5%.4


The second question not yet solved is the long-term efficacy of ablation therapy. A recent report with five-year follow-up by the Haissaguerre group has revealed that arrhythmia-free survival rates reaches 29% after a single catheter ablation procedure, and 63% with a mean of two procedures per patient.5 These are discouraging results for such invasive and expensive therapies. Still, we need to know what will be the long-term results with the more consisting surgery-produced ablation lines.


In our opinion and with the actual scientific evidence in hand, most patients with symptomatic paroxysmal or persistent atrial fibrillation refractory to antiarrhythmic therapy should undergo catheter ablation. But after one catheter ablation failure or with left atrium dilatation over 43mm to 45mm, patients would most probably benefit better by thoracoscopic surgery.


Manuel Castella, Department of Cardiovascular Surgery, Hospital Clinic, University of Barcelona, Spain, was a principal investigator in the FAST trial.


References

1. Boersma et al. Circulation 2011. In press

2. Calkins et al. Europace 2007; 9:335–79

3. Wann et al. Circulation 2011; 123:104–23

4. Cappato et al. Circulation 2005;111:1100–05

5. Weerasooriya et al. J Am Coll Cardiol 2011; 57: 160–66




Add New Comment

Most popular


Benefit of anticoagulation in AF patients with a low risk of stroke questioned
Thursday, 18 Jun 2015
The results from a retrospective study, based on a large dataset (over 140,000 patients), have cast doubt on the benefit of routine oral anticoagulants for patients with atrial fibrillation and low ... Benefit of anticoagulation in AF patients with a low risk of stroke questioned

New stem cell delivery method shows promise for treating end stage heart failure
Monday, 27 Jul 2015
A new clinical trial to test how a high dose of stem cells delivered via a method called retrograde coronary sinus infusion affects end stage heart failure patients is showing promising results. New stem cell delivery method shows promise for treating end stage heart failure

Friday, 24 Jul 2015
Key topics from the hot line sessions of ESC 2015 include atrial fibrillation, pacing, acute myocardial infarction, heart failure, hypertension, diabetes mellitus, pharmacology and coronary artery ... ESC announces hot line sessions highlights

Features


Highlights EHRA EUROPACE-CARDIOSTIM 2015: Interview with Michael Glikson
Thursday, 16 Jul 2015
Michael Glikson (director of Davidai Arrhythmia Center, Heart Center, Sheba Medical Center, Tel Hashomer, Israel), vice-chairperson scientific programme for EHRA EUROPACE-CARDIOSTIM 2015, talks to C... Highlights EHRA EUROPACE-CARDIOSTIM 2015: Interview with Michael Glikson

Mechanical transvenous lead extraction vs. laser lead extraction
Tuesday, 30 Jun 2015
Maria Grazia Bongiorni (Pisa, Italy) compares mechanical transvenous lead extraction vs. laser lead extraction approaches with supporting evidence from key randomised controlled trials in the field. Mechanical transvenous lead extraction vs. laser lead extraction

Profiles


Cecilia Linde
Monday, 22 Jun 2015
Cecilia Linde speaks to Cardiac Rhythm News about her work on a research platform for new onset ... Cecilia Linde

Michael Gold
Wednesday, 03 Jun 2015
William Gold spoke to Cardiac Rhythm News about his involvement in various clinical trials, his ... Michael Gold

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions